Demographics and clinical characteristics
| Variables | AD-MCI† (n=18) | PD‡ (n=18) | Controls (n=19) | p Valus* |
|---|---|---|---|---|
| Age, years | 65.6±5.6 (55–77) | 66.7±5.1 (59–75) | 64.6±6.5 (52–77) | 0.537 |
| Female sex, n | 9 (50%) | 9 (50%) | 13 (68%) | 0.424 |
| Disease duration, years | 2.4±1.7 (0.5–7) | 2.2±1.1 (1–5) | – | 0.181 |
| MMSE§ score | 27.3±1.8 (24–30) | 28.8±1.4 (26–30) | 29.5±0.5 (29–30) | 0.000 |
| GDS¶, categories 1/2/3, n | 0/0/18 | 8/3/7 | 19/0/0 | 0.000 |
| Education, years | 12.8±3.3 (8–18) | 11.3±3.5 (7–18) | 11.8±2.4 (8–16) | 0.345 |
| Fazekas; mean white matter score | 1.0±0.8 (0–2) | 0.9±0.7 (0–2) | 0.8±0.6 (0–2) | 0.779 |
| Fazekas; mean periventricular score | 1.1±0.5 (0–2) | 1.1±0.5 (0–2) | 1.1±0.5 (0–2) | 0.927 |
| Cerebrovascular composite score** | 1.7±1.0 (0–3) | 1.6±1.4 (0–4) | – | 0.894 |
The three groups did not differ regarding age, sex, years of education, cerebrovascular burden and Fazekas score.
Numbers represent means±SD (range) unless otherwise indicated.
*Significant at the p<0.05 level.
†Alzheimer's disease—mild cognitive impairment.
‡Parkinson's disease.
§Mini-Mental State Examination.
¶Global Deterioration Scale, category 1=normal, category 2=subjective cognitive impairment, category 3=mild cognitive impairment.
**Composite score from 0 to 6 were 0 indicates no cerebrovascular burden, 6 indicates a maximum disease burden.